Genetic Variation and Exposure Related Risk Estimation: Will Toxicology Enter a New Era? DNA Repair and Cancer as a Paradigm

With the vast technological and informational resources increasingly available from investments in “genomics,” toxicology and much of biological science, is faced with previously undreamed of opportunities and equally daunting challenges. The ability to generate the large quantities of data becoming routinely available could not be imagined a decade ago. The complexities of data analysis are increasingly the rate-limiting element in scientific advances. The expectations that these large scientific investments will reduce the incidence of human disease and improve health are very high. An emphasis on genetic variation and Toxicogenetics is expected to yield risk estimates for specific rather than average individuals and individuals with varied lifestyles and complex patterns of exposure. Examples from studies of polymorphic variation in DNA repair genes in the healthy population and cancer risk highlight the complexity and challenges of incorporating genetic variation into quantitative estimates of risk associated with environmentally relevant exposures. Similar issues exist in selecting the animal models most appropriate for predicting human risk from environmental exposures to toxic agents.

[1]  M. Bleavins,et al.  Pharmacogenetic application in drug development and clinical trials. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[2]  D. Cheo,et al.  Cancer predisposition in mutant mice defective in multiple genetic pathways: uncovering important genetic interactions. , 2001, Mutation research.

[3]  G. Boivin,et al.  Enhanced Tumor Formation in Mice Heterozygous for Blm Mutation , 2002, Science.

[4]  K. Buetow,et al.  The use of common genetic polymorphisms to enhance the epidemiologic study of environmental carcinogens. , 2001, Biochimica et biophysica acta.

[5]  R C Garner,et al.  The role of DNA adducts in chemical carcinogenesis. , 1998, Mutation research.

[6]  C. Harris,et al.  Cancer risk and low-penetrance susceptibility genes in gene-environment interactions. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  M. Ingelman-Sundberg,et al.  Unravelling the functional genomics of the human CYP2D6 gene locus. , 2001, Pharmacogenetics.

[8]  E. Mark,et al.  Polymorphisms in the Dna Repair Genes Xrcc1 and Ercc2 and Biomarkers of Dna Damage in Human Blood Mononuclear Cells Cross-complementing Group 1) than in 399arg/arg Carriers of Breaks following Base Excision Repair (ber) Resulting From , 2022 .

[9]  P Vineis,et al.  Markers of DNA repair and susceptibility to cancer in humans: an epidemiologic review. , 2000, Journal of the National Cancer Institute.

[10]  Hongbing Shen,et al.  Modulation of repair of ultraviolet damage in the host-cell reactivation assay by polymorphic XPC and XPD/ERCC2 genotypes. , 2002, Carcinogenesis.

[11]  D. Boomsma,et al.  Inherited susceptibility to bleomycin-induced chromatid breaks in cultured peripheral blood lymphocytes. , 1999, Journal of the National Cancer Institute.

[12]  H. Norppa,et al.  Chromosomal aberrations in lymphocytes predict human cancer independently of exposure to carcinogens. European Study Group on Cytogenetic Biomarkers and Health. , 2000, Cancer research.

[13]  L. Povirk,et al.  DNA damage and mutagenesis by radiomimetic DNA-cleaving agents: bleomycin, neocarzinostatin and other enediynes. , 1996, Mutation research.

[14]  B. Delaney Dyspepsia management in the millennium: to test and treat or not? , 2003, Gut.

[15]  H. Morgenstern,et al.  Environmental tobacco smoking, mutagen sensitivity, and head and neck squamous cell carcinoma. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[16]  P. Vineis Molecular epidemiology: Low‐dose carcinogens and genetic susceptibility , 1997, International journal of cancer.

[17]  P. Hsieh,et al.  Molecular mechanisms of DNA mismatch repair. , 2001, Mutation research.

[18]  C. Wolf,et al.  Science, medicine, and the future: Pharmacogenetics. , 2000, BMJ.

[19]  I. M. Jones,et al.  Challenges and complexities in estimating both the functional impact and the disease risk associated with the extensive genetic variation in human DNA repair genes. , 2003, Mutation research.

[20]  Lee Bennett,et al.  Genomic interrogation of mechanism(s) underlying cellular responses to toxicants. , 2002, Toxicology.

[21]  H. Mohrenweiser,et al.  Amino acid substitution variants of APE1 and XRCC1 genes associated with ionizing radiation sensitivity. , 2001, Carcinogenesis.

[22]  R. Hammer,et al.  Heterozygosity for the mouse Apex gene results in phenotypes associated with oxidative stress. , 2001, Cancer research.

[23]  D. Purdie,et al.  Mice heterozygous for mutation in Atm, the gene involved in ataxia-telangiectasia, have heightened susceptibility to cancer , 2002, Nature Genetics.

[24]  Warren C. Lathe,et al.  Prediction of deleterious human alleles. , 2001, Human molecular genetics.

[25]  J. Moult,et al.  SNPs, protein structure, and disease , 2001, Human mutation.

[26]  A. Nafziger,et al.  Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. , 2002, The American journal of medicine.

[27]  B. Ponder Cancer genetics , 2001, Nature.

[28]  T. Zacharewski,et al.  Genetics and Susceptibility to Toxic Chemicals: Do You (or Should You) Know Your Genetic Profile? , 2003, Journal of Pharmacology and Experimental Therapeutics.

[29]  W. Kalow Pharmacogenetics, pharmacogenomics, and pharmacobiology , 2001, Clinical pharmacology and therapeutics.

[30]  T. Sellers,et al.  Lung cancer detection and prevention: evidence for an interaction between smoking and genetic predisposition. , 1992, Cancer research.

[31]  P. Bork,et al.  Human non-synonymous SNPs: server and survey. , 2002, Nucleic acids research.

[32]  I. M. Jones,et al.  Elevated frequencies of hypoxanthine phosphoribosyltransferase lymphocyte mutants are detected in Russian liquidators 6 to 10 years after exposure to radiation from the Chernobyl nuclear power plant accident. , 1999, Mutation research.

[33]  S. Haas,et al.  Transgenic systems in studies on genotoxicity of alkylating agents: critical lesions, thresholds and defense mechanisms. , 1998, Mutation research.

[34]  T. Beaty,et al.  Genomewide screen and identification of gene-gene interactions for asthma-susceptibility loci in three U.S. populations: collaborative study on the genetics of asthma. , 2001, American journal of human genetics.

[35]  B. Trock,et al.  DNA Repair as A Susceptibility Factor in Chronic Diseases in Human Populations , 1999 .

[36]  M. King,et al.  Insights into the functions of BRCA1 and BRCA2. , 2000, Trends in genetics : TIG.

[37]  I. M. Jones,et al.  Three Somatic Genetic Biomarkers and Covariates in Radiation-Exposed Russian Cleanup Workers of the Chernobyl Nuclear Reactor 6–13 Years after Exposure , 2002, Radiation research.

[38]  Richard D. Wood,et al.  Human DNA Repair Genes , 2001, Science.

[39]  P. Walsh Heterogeneity of genetic alterations in prostate cancer: evidence of the complex nature of the disease. , 2002, The Journal of urology.

[40]  J M Silva,et al.  Chromosomal aberrations in lymphocytes from car painters. , 1996, Mutation research.

[41]  I. M. Jones,et al.  Identification of 127 amino acid substitution variants in screening 37 DNA repair genes in humans. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[42]  F. Hossler,et al.  PERIPHERAL BLOOD -- Lymphocyte , 1998 .

[43]  M. Spitz,et al.  Rapid assessment of repair of ultraviolet DNA damage with a modified host-cell reactivation assay using a luciferase reporter gene and correlation with polymorphisms of DNA repair genes in normal human lymphocytes. , 2002, Mutation research.

[44]  D. Easton,et al.  Cancer mortality in relatives of women with breast cancer: The OPCS study , 1996, International journal of cancer.

[45]  D. Flockhart,et al.  Cytochrome P450 3A pharmacogenetics: the road that needs traveled , 2003, The Pharmacogenomics Journal.

[46]  M. Oscarson Pharmacogenetics of Drug Metabolising Enzymes: Importance for Personalised Medicine , 2003, Clinical chemistry and laboratory medicine.

[47]  U. Vogel,et al.  Polymorphisms of the DNA repair gene XPD: correlations with risk of basal cell carcinoma revisited. , 2001, Carcinogenesis.

[48]  Larry Borish,et al.  5. Genetics of hypersensitivity. , 2003, The Journal of allergy and clinical immunology.

[49]  D. Easton,et al.  Cancer mortality in relatives of women with ovarian cancer: The OPCS study , 1996, International journal of cancer.

[50]  David H Phillips,et al.  DNA adducts as markers of exposure and risk. , 2005, Mutation research.

[51]  J. Hoeijmakers Genome maintenance mechanisms for preventing cancer , 2001, Nature.

[52]  G. Petersen,et al.  Familial aggregation: sorting susceptibility from shared environment. , 2000, Journal of the National Cancer Institute.

[53]  Howard L McLeod,et al.  Pharmacogenomics--drug disposition, drug targets, and side effects. , 2003, The New England journal of medicine.

[54]  P. Vineis,et al.  Studies of DNA repair and human cancer: an update , 2002 .

[55]  W. Tan,et al.  Sequence variations in the DNA repair gene XPD and risk of lung cancer in a Chinese population , 2003, International journal of cancer.

[56]  Gupta Rc,et al.  Background DNA damage for endogenous and unavoidable exogenous carcinogens: a basis for spontaneous cancer incidence? , 1999 .

[57]  D. Christiani,et al.  Polymorphisms in the DNA repair genes XRCC1 and ERCC2, smoking, and lung cancer risk. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[58]  M. Tockman,et al.  Gene-environment interactions between the codon 194 polymorphism of XRCC1 and antioxidants influence lung cancer risk. , 2003, Anticancer research.

[59]  C. Ulrich,et al.  Polymorphisms in DNA repair genes and associations with cancer risk. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[60]  M. Spitz,et al.  XPA polymorphism associated with reduced lung cancer risk and a modulating effect on nucleotide excision repair capacity. , 2003, Carcinogenesis.

[61]  I. M. Jones,et al.  Variation in DNA repair is a factor in cancer susceptibility: a paradigm for the promises and perils of individual and population risk estimation? , 1998, Mutation research.

[62]  M. Spitz,et al.  Benzo[a]pyrene diol epoxide and bleomycin sensitivity and susceptibility to cancer of upper aerodigestive tract. , 1998, Journal of the National Cancer Institute.

[63]  D. Cheo,et al.  Cancer predisposition in mutant mice defective in the XPC DNA repair gene. , 1999, Progress in experimental tumor research.

[64]  M Schwab,et al.  Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. , 2001, Pharmacogenetics.

[65]  F. Perera Molecular epidemiology: on the path to prevention? , 2000, Journal of the National Cancer Institute.

[66]  N. Cox Challenges in identifying genetic variation affecting susceptibility to type 2 diabetes: examples from studies of the calpain-10 gene. , 2001, Human molecular genetics.

[67]  P. Lemotte,et al.  DNA damage induced in human diploid cells by decay of incorporated radionuclides. , 1984, Cancer research.

[68]  G. H. Bush,et al.  Pharmacogenetics , 1968 .

[69]  R. Kucherlapati,et al.  Haploinsufficiency of Flap endonuclease (Fen1) leads to rapid tumor progression , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[70]  H. Bernstein,et al.  DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis. , 2002, Mutation research.

[71]  D. Evans,et al.  Heritability of cellular radiosensitivity: a marker of low-penetrance predisposition genes in breast cancer? , 1999, American journal of human genetics.

[72]  H. Norppa,et al.  Chromosomal aberrations in lymphocytes predict human cancer: a report from the European Study Group on Cytogenetic Biomarkers and Health (ESCH). , 1998, Cancer research.

[73]  V. Slavkovich,et al.  DNA repair gene XPD and susceptibility to arsenic-induced hyperkeratosis. , 2003, Toxicology letters.

[74]  R. Gupta,et al.  Background DNA damage for endogenous and unavoidable exogenous carcinogens: a basis for spontaneous cancer incidence? , 1999, Mutation research.

[75]  P. Doris Hypertension Genetics, Single Nucleotide Polymorphisms, and the Common Disease:Common Variant Hypothesis , 2002, Hypertension.

[76]  R. Weinshilboum Inheritance and drug response. , 2003, The New England journal of medicine.

[77]  A. Daly,et al.  Pharmacogenetics of the major polymorphic metabolizing enzymes , 2003, Fundamental & clinical pharmacology.

[78]  D. Phillips,et al.  Polymorphisms of the GSTP1 and GSTM1 genes and PAH‐DNA adducts in human mononuclear white blood cells , 2000, Environmental and molecular mutagenesis.

[79]  S. Henikoff,et al.  Accounting for human polymorphisms predicted to affect protein function. , 2002, Genome research.

[80]  D. Brenner,et al.  Atm heterozygous mice are more sensitive to radiation-induced cataracts than are their wild-type counterparts , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[81]  K. Tanaka,et al.  Importance of DNA repair in carcinogenesis: evidence from transgenic and gene targeting studies. , 2001, Mutation research.

[82]  J. Carlquist,et al.  Cardiovascular Pharmacogenomics: Current Status, Future Prospects , 2003, Journal of cardiovascular pharmacology and therapeutics.

[83]  L. Brooks,et al.  A DNA polymorphism discovery resource for research on human genetic variation. , 1998, Genome research.

[84]  N. Risch Searching for genetic determinants in the new millennium , 2000, Nature.

[85]  H. Wallin,et al.  Psoriasis patients with basal cell carcinoma have more repair-mediated DNA strand-breaks after UVC damage in lymphocytes than psoriasis patients without basal cell carcinoma. , 2000, Cancer letters.

[86]  G. Siest,et al.  Pharmacogenomics of Drugs Affecting the Cardiovascular System , 2003, Clinical chemistry and laboratory medicine.

[87]  K. Turteltaub,et al.  Methods of Dna Adduct Determination and Their Application to Testing Compounds for Genotoxicity , 2022 .

[88]  R. Fanelli,et al.  Carcinogen-DNA adducts as tools in risk assessment. , 1999, Advances in experimental medicine and biology.

[89]  W. Evans,et al.  Pharmacogenomics: marshalling the human genome to individualise drug therapy , 2003, Gut.

[90]  R. Patel,et al.  DNA repair proficiency in breast cancer patients and their first‐degree relatives , 1997, International journal of cancer.

[91]  K. Lohman,et al.  Polymorphisms of XRCC1 and XRCC3 genes and susceptibility to breast cancer. , 2003, Cancer letters.

[92]  T. Lindahl Instability and decay of the primary structure of DNA , 1993, Nature.

[93]  I. M. Jones,et al.  Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. , 1998, Cancer research.

[94]  J. Ihle The Challenges of Translating Knockout Phenotypes into Gene Function , 2000, Cell.

[95]  D. Kuijpers,et al.  Basal Cell Carcinoma , 2002, American journal of clinical dermatology.

[96]  R. Weinshilboum,et al.  Thiopurine pharmacogenetics: clinical and molecular studies of thiopurine methyltransferase. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[97]  M. Spitz,et al.  A parallel study of in vitro sensitivity to benzo[a]pyrene diol epoxide and bleomycin in lung carcinoma cases and controls , 1998, Cancer.

[98]  Bruce M Psaty,et al.  Genomics and Medicine: Distraction, Incremental Progress, or the Dawn of a New Age? , 2003, Annals of Internal Medicine.

[99]  M. Nair,et al.  DNA repair proficiency: a potential marker for identification of high risk members in breast cancer families. , 1998, Cancer letters.

[100]  N. Risch,et al.  The genetic epidemiology of cancer: interpreting family and twin studies and their implications for molecular genetic approaches. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[101]  J. Hopper,et al.  Genetic epidemiology of female breast cancer. , 2001, Seminars in cancer biology.

[102]  F. Perera,et al.  DNA adducts as markers of exposure to carcinogens and risk of cancer , 2000, International journal of cancer.

[103]  D. Bell,et al.  XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency. , 1999, Cancer research.

[104]  K. Hemminki,et al.  DNA adducts as a marker for cancer risk? , 2001, International journal of cancer.

[105]  W. Kalow,et al.  Pharmacogenetics and personalised medicine , 2002, Fundamental & clinical pharmacology.

[106]  F. Perera,et al.  Association between polycyclic aromatic hydrocarbon-DNA adduct levels in maternal and newborn white blood cells and glutathione S-transferase P1 and CYP1A1 polymorphisms. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[107]  S. Henikoff,et al.  Predicting deleterious amino acid substitutions. , 2001, Genome research.

[108]  Eric Boerwinkle,et al.  Genetics of blood pressure, hypertensive complications, and antihypertensive drug responses. , 2003, Pharmacogenomics.

[109]  D. Cheo,et al.  Ultraviolet B radiation-induced skin cancer in mice defective in the Xpc, Trp53, and Apex (HAP1) genes: genotype-specific effects on cancer predisposition and pathology of tumors. , 2000, Cancer research.

[110]  G. Orphanides Toxicogenomics: challenges and opportunities. , 2003, Toxicology letters.

[111]  I. M. Jones,et al.  Human in vivo somatic mutation measured at two loci: individuals with stably elevated background erythrocyte glycophorin A (gpa) variant frequencies exhibit normal T-lymphocyte hprt mutant frequencies. , 1998, Mutation research.

[112]  K. Fidelis,et al.  Functional characterization of Ape1 variants identified in the human population. , 2000, Nucleic acids research.

[113]  M. Daly,et al.  A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms , 2001, Nature.

[114]  E. Friedberg,et al.  DNA Repair and Mutagenesis , 2006 .

[115]  Klaus Lindpaintner,et al.  Pharmacogenetics and the future of medical practice. , 2002, Journal of molecular medicine.

[116]  A. Povey DNA Adducts: Endogenous and Induced , 2000, Toxicologic pathology.

[117]  W. Lutz Dose-response relationships in chemical carcinogenesis reflect differences in individual susceptibility. Consequences for cancer risk assessment, extrapolation, and prevention , 1999, Human & experimental toxicology.

[118]  D. Schild,et al.  Homologous recombinational repair of DNA ensures mammalian chromosome stability. , 2001, Mutation research.